三个皮匠报告—— 严选型全行业研究报告分享下载平台，您的专属行业智库！
欢迎来到三个皮匠报告！
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置：
首页
>
行业数据
>
中国vs欧美：EGFR突变患者占比
中国vs欧美：EGFR突变患者占比
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式：PNG
图片大小：58KB
图片尺寸：1819*786
同报告图片
/
4
fCDlnLDljLogICB8IEVHRlLnqoHlj5jmgqPogIUgfCDml6BFR0ZS56qB5Y+Y5oKj6ICFIHwKfC0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS18Cnwg5Lit5Zu9ICAgfCAzOC40ICAgICAgICAgfCA2MS42ICAgICAgICAgICB8Cnwg576O5rSyICAgfCAyNC4yICAgICAgICAgfCA3NS44ICAgICAgICAgICB8Cnwg5qyn5rSyICAgfCAxNC4xICAgICAgICAgfCA4NS45ICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJpDYW5jZXIgVHJlYXQgUmVzIENvbW11bi4gMjAyMTsyOToxMDA0NjLvvIzljY7ms7DnoJTnqbY=
fCDooajovr7msLTlubMgfCDmr5TkvosgfAp8LS0tLS0tLS0tfC0tLS0tLXwKfCBDUFPiiaUxMCB8IDMzJSAgfAp8IDXiiaRDUFM8MTAgfCAxNiUgIHwKfCAx4omkQ1BTPDUgfCAxMyUgIHwKfCBDUFM8MSB8IDM4JSAgfAoK6LWE5paZ5p2l5rqQ77yaRnJvbnQgSW1tdW5vbC4gMjAyMjsxMzo3ODM2OTXvvIzljY7ms7DnoJTnqbY=
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
所属报告：
康方生物-深耕双抗力助腾飞-221125（52页）.pdf
打包全文图表
相关数据
SHR-A2009用于EGFR突变型NSCLC的1期临床研究结果
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
收藏
行业数据
2026-05-28
原图定位
查看详情
Ph2a临床研究Sefaxersen尿蛋白及eGFR数据
IyMjIOWwv+ibi+eZveaMh+aghyAlIOWPmOWMlu+8iOWfuue6v+WvueavlO+8iQp8IOaMh+aghyAgICAgICAgIHwgV2VlayAyOSAoJSBDaGFuZ2UgZnJvbSBiYXNlbGluZSkgfCBMYXN0IG1lYXN1cmVtZW50ICglIENoYW5nZSBmcm9tIGJhc2VsaW5lKSB8CnwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgVVBFIChnL2QpICAgIHwgLTQyICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAtNDUgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgVVBDUiAoZy9nKSAgIHwgLTQxICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAtNDMgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgVUFDUiAoZy9nKSAgIHwgLTQ0ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAtNDcgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CgoKIyMjIGVHRlIg5Y+Y5YyW5Y+K5qC35pys6YePCnwgU3R1ZHkgd2VlayB8IENoYW5nZSBpbiBlR0ZSIChtbC9taW4gcGVyIDEuNzMgbcKyKSB8IE51bWJlciBvZiBzdWJqZWN0cyAobikgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBCTCAgICAgICAgIHwgMCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjMgICAgICAgICAgICAgICAgICAgICB8CnwgMyAgICAgICAgICB8IC0xICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDIzICAgICAgICAgICAgICAgICAgICAgfAp8IDUgICAgICAgICAgfCAtMyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAyMyAgICAgICAgICAgICAgICAgICAgIHwKfCA3ICAgICAgICAgIHwgMCAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjMgICAgICAgICAgICAgICAgICAgICB8CnwgOSAgICAgICAgICB8IDEgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDIzICAgICAgICAgICAgICAgICAgICAgfAp8IDEzICAgICAgICAgfCAzICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAyMyAgICAgICAgICAgICAgICAgICAgIHwKfCAxNyAgICAgICAgIHwgLTEgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjMgICAgICAgICAgICAgICAgICAgICB8CnwgMjEgICAgICAgICB8IDEgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDIxICAgICAgICAgICAgICAgICAgICAgfAp8IDI1ICAgICAgICAgfCAzICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCAyMiAgICAgICAgICAgICAgICAgICAgIHwKfCAyNyAgICAgICAgIHwgMiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwgMjIgICAgICAgICAgICAgICAgICAgICB8CnwgMjkgICAgICAgICB8IDMgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IDIzICAgICAgICAgICAgICAgICAgICAgfAoKCioq6LWE5paZ5p2l5rqQKirvvJoqS2lkbmV5IEludGVybmF0aW9uYWwq77yM5Zu95L+h6K+B5Yi457uP5rWO56CU56m25omA5pW055CG
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph3NeflgArd研究第24个月eGFR及uPCR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph1/2ADU-CL-19研究中Zigakibart组受试者100周uPCR及eGFR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
Ph1/2aRUBY-3研究中Povetacicept80mg剂量组第48周uPCR及eGFR数据
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
收藏
行业数据
2026-03-13
原图定位
查看详情
图3 mCRC中EGFR抑制剂的美国收入（2004-2017）
收藏
行业数据
2026-02-13
原图定位
查看详情
三代EGFR药物适应症对比（2025年新增两款）
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
收藏
行业数据
2026-02-04
原图定位
查看详情
第二代EGFR-TKI不同企业竞争格局
IyMjIOS6jOS7o0VHRlItVEtJ5LiN5ZCM5LyB5Lia56ue5LqJ5qC85bGA5pWw5o2u6KGo77yIMjAxNSAtIDIwMjFIMe+8iQp8IOW5tOS7vSAgIHwg6I2v54mp57G75Z6LICAgICAgIHwg5LyB5LiaICAgICAgICAgfCDplIDllK7pop3vvIjkur/lhYPkurrmsJHluIHvvIkgfAp8LS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMTUgICB8IOmYv+azleabv+WwvCAgICAgICB8IOm9kOmygeWItuiNryAgICAgfCAwLjAgICAgICAgICAgICAgICAgICB8CnwgMjAxNSAgIHwg6Zi/5rOV5pu/5bC8ICAgICAgIHwg5YuD5p6X5qC85q635qC857+wIHwgMC4wICAgICAgICAgICAgICAgICAgfAp8IDIwMTYgICB8IOmYv+azleabv+WwvCAgICAgICB8IOm9kOmygeWItuiNryAgICAgfCAwLjAgICAgICAgICAgICAgICAgICB8CnwgMjAxNiAgIHwg6Zi/5rOV5pu/5bC8ICAgICAgIHwg5YuD5p6X5qC85q635qC857+wIHwgMC4wICAgICAgICAgICAgICAgICAgfAp8IDIwMTcgICB8IOmYv+azleabv+WwvCAgICAgICB8IOm9kOmygeWItuiNryAgICAgfCAwLjAgICAgICAgICAgICAgICAgICB8CnwgMjAxNyAgIHwg6Zi/5rOV5pu/5bC8ICAgICAgIHwg5YuD5p6X5qC85q635qC857+wIHwgMC4wICAgICAgICAgICAgICAgICAgfAp8IDIwMTggICB8IOmYv+azleabv+WwvCAgICAgICB8IOm9kOmygeWItuiNryAgICAgfCAwLjIgICAgICAgICAgICAgICAgICB8CnwgMjAxOCAgIHwg6Zi/5rOV5pu/5bC8ICAgICAgIHwg5YuD5p6X5qC85q635qC857+wIHwgMC4yICAgICAgICAgICAgICAgICAgfAp8IDIwMTkgICB8IOmYv+azleabv+WwvCAgICAgICB8IOm9kOmygeWItuiNryAgICAgfCAwLjAgICAgICAgICAgICAgICAgICB8CnwgMjAxOSAgIHwg6Zi/5rOV5pu/5bC8ICAgICAgIHwg5YuD5p6X5qC85q635qC857+wIHwgMy4wICAgICAgICAgICAgICAgICAgfAp8IDIwMjAgICB8IOmYv+azleabv+WwvCAgICAgICB8IOm9kOmygeWItuiNryAgICAgfCAwLjAgICAgICAgICAgICAgICAgICB8CnwgMjAyMCAgIHwg6Zi/5rOV5pu/5bC8ICAgICAgIHwg5YuD5p6X5qC85q635qC857+wIHwgNS4xICAgICAgICAgICAgICAgICAgfAp8IDIwMjFIMSB8IOmYv+azleabv+WwvCAgICAgICB8IOm9kOmygeWItuiNryAgICAgfCAwLjIgICAgICAgICAgICAgICAgICB8CnwgMjAyMUgxIHwg6Zi/5rOV5pu/5bC8ICAgICAgIHwg5YuD5p6X5qC85q635qC857+wIHwgMy4yICAgICAgICAgICAgICAgICAgfAp8IDIwMTUgICB8IO+8iOi+ieeRnuS6p+WTge+8iSAgIHwg6L6J55GeICAgICAgICAgfCAwLjAgICAgICAgICAgICAgICAgICB8CnwgMjAxNiAgIHwg77yI6L6J55Ge5Lqn5ZOB77yJICAgfCDovonnkZ4gICAgICAgICB8IDAuMCAgICAgICAgICAgICAgICAgIHwKfCAyMDE3ICAgfCDvvIjovonnkZ7kuqflk4HvvIkgICB8IOi+ieeRniAgICAgICAgIHwgMC4wICAgICAgICAgICAgICAgICAgfAp8IDIwMTggICB8IO+8iOi+ieeRnuS6p+WTge+8iSAgIHwg6L6J55GeICAgICAgICAgfCAwLjAgICAgICAgICAgICAgICAgICB8CnwgMjAxOSAgIHwg77yI6L6J55Ge5Lqn5ZOB77yJICAgfCDovonnkZ4gICAgICAgICB8IDAuNiAgICAgICAgICAgICAgICAgIHwKfCAyMDIwICAgfCDvvIjovonnkZ7kuqflk4HvvIkgICB8IOi+ieeRniAgICAgICAgIHwgMS43ICAgICAgICAgICAgICAgICAgfAp8IDIwMjFIMSB8IO+8iOi+ieeRnuS6p+WTge+8iSAgIHwg6L6J55GeICAgICAgICAgfCAyLjIgICAgICAgICAgICAgICAgICB8CgoKIyMjIOi1hOaWmeadpea6kCAgCu+8iOazqO+8muWOn+WbvuihqOacquaYjuehruagh+azqOWFt+S9k+i1hOaWmeadpea6kO+8jOatpOWkhOWfuuS6juWbvuihqOWGheWuueaVtOeQhuWRiOeOsOOAgu+8iQ==
收藏
竞争格局
2026-01-08
原图定位
查看详情
第一代EGFR-TKI不同企业竞争格局
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
收藏
竞争格局
2026-01-08
原图定位
查看详情
Iza-bren已开展临床研究的癌种（左图中以红字标明）以及EGFR和HER3在各种上皮肿瘤中的
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
收藏
行业数据
2025-12-26
原图定位
查看详情
EGFR/HER3ADC全球格局
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
收藏
竞争格局
2025-12-26
原图定位
查看详情
图表20EGFR耐药后NSCLC试验数据比
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
收藏
行业数据
2025-12-03
原图定位
查看详情
和誉ABSK043的临床定位以及未来结合EGFR/KRAS等小分子抑制剂在NSCLC中布局的管线矩阵
fCDkurrnvqQgICB8IEVHRlJtdXQgfCBLUkFTbXV0IHwKfC0tLS0tLS0tfC0tLS0tLS0tLXwtLS0tLS0tLS18Cnwg6KW/5pa55Lq6576kIHwgMjAlICAgICB8IDI1JSAgICAgfAp8IOS6mua0suS6uue+pCB8IDUwJSAgICAgfCAxMCUgICAgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuFBQVA==
收藏
行业数据
2025-10-10
原图定位
查看详情
EGFR突变NSCLC患者推荐用药（CSCO及NCCN指南）
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
收藏
行业数据
2025-09-23
原图定位
查看详情
截至2025年9月，全球共6款EGFR单抗ADC药物进入临床
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
收藏
行业数据
2025-09-23
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模（亿美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模（亿美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模（百万美元）
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
非小细胞肺癌全覆盖 中国非小细胞肺癌患者池庞大。依据弗若斯特沙利文，2021 年中国肺癌新患者约 81 万人， 其中 85% 为非小细胞肺癌。EGFR 突变是肺癌中最为常 见的驱动基因突变类型，且中国患者群体中的突变频率较欧美更高：中国约 38.4%晚期非小细胞肺癌患者存在 EGFR 突变，远高于美洲人群的 24.2%与欧洲的 14.1%。EGFR 突变通常导致病人的预后更差，但携带此驱动基因突变的病人也对 EGFR-TKI 治疗更为敏感。
行业数据
原图定位
当前图表所属：
康方生物-深耕双抗力助腾飞-221125（52页）.pdf
表达水平与HER2
表现金流量
卡度尼利单抗：PD-1与CTLA-4同时存在时亲和力高于单抗
康方生物：收入预测
下载图片或Excel，需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利，扫码领取！
关注公众号『三个皮匠报告』，免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码？
验证即登录，未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》
研搜
0731-84720580
商务合作：really158d
下载Excel
下载图片
原图定位
打包全文图表
收藏
2026-05-28
原图定位
微信扫码登录
手机快捷登录
账号登录
